Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| DTS INC | DTSI | 6.89% |
| ANIKA THERAP | ANIK | 6.04% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
On May 30, 2012, worldwide medical devices provider, Teleflex Incorporated (TFX - Snapshot Report) announced that it has received the U.S. Food and Drug Administration (FDA) 510(k) clearance for its Arrow FlexTip Plus Closed Tip, Multi-Port epidural catheter. This will enhance the company’s Arrow catheter portfolio and strengthen its Critical Care segment.
The Critical Care segment recorded 7.5% increase in revenue to $256.2 million during the first quarter of fiscal 2012, aided by robust sales of catheters. Total revenue came in at $387.8 million, up 9.5% year over year. Current product development underlines the company’s ability to further boost its top-line growth as new products and price mark-up accounted for increase in total revenue in the last quarter.
The company’s focus on attaining profitable and consistent growth with new product introduction and portfolio expansion is yielding results. Teleflex earlier received FDA 510(k) clearance for its antithrombogenic claims on the Arrow Peripherally Inserted Central Catheter (PICC) with Chlorag+ard technology.
The Arrow FlexTip Plus Closed Tip, Multi-Port epidural catheter is a development on the company’s market leading Arrow FlexTip Plus Open Tip, Single-Port epidural catheter. The Open Tip, Single-Port epidural catheter, the only coil-reinforced catheter, is well regarded in its ability to reduce complications which other epidural catheters could not prevent. Examples include vein cannulations and paresthesia. The statistical success of Open Tip, Single-Port catheter is supported by more than a decade of clinical data.
The FlexiTip Plus Closed Tip, Multi-Port has a soft flexible tip with four lateral holes and provides exceptional kink resistance and is based on proven technology. The new addition to the Arrow catheter family will further support clinicians by reducing the problems faced by anesthesiologists on a regular basis. Management therefore believes that the FlexiTip Plus Closed Tip, Multi-Port can help anesthesiologists in improving the quality and standard of patient care.
The new product uses the same technology as the Open Tip, Single Port catheter but its addition to the Arrow FlexiTip Plus will render various drug dispersion choices to critically aid clinical results. The FlexiTip Plus catheters are made of polyurethane unlike the majority of other spring wound catheters which are made of nylon.
Teleflex, headquartered in Limerick, Pennsylvania is a manufacturer and provider of medical devices used in critical care and surgery. Its initiative of developing new, innovative products should help drive sales further. Mesa Laboratories (MLAB - Snapshot Report) and Given Imaging (GIVN), which operate in similar business segments, are also making efforts to boost their top-line growth via new product introduction and acquisition.
Teleflex currently retains a Zacks #3 Rank, which translates into a short-term Hold rating.
Get the full Snapshot Report on TFX - FREE
Get the full on GIVN - FREE
Get the full Snapshot Report on MLAB - FREE